摘要
微小残留病(MRD)已被常规用于急性髓细胞白血病(AML)患者的疗效评估和复发预测。本文从异基因造血干细胞移植适应证、移植方式、预处理方案以及移植后复发预防等方面讨论了MRD指导的个体化分层治疗。未来的研究应聚焦AML患者MRD检测及干预新方法的建立。
Minimal residual disease(MRD)has been used routinely for curative effect evaluation and relapse prediction for patients with acute myeloid leukemia(AML).It discussed MRD directed individual therapy for AML in view of transplant indications,transplant modality selection,conditioning regimen and relapse prevention after allogeneic stem cell transplantation.Future directions should focus on the establishment of new methods for MRD detection and novel strategies for MRD intervention.
作者
常英军
赵晓甦
CHANG Yingjun;ZHAO Xiaosu(Peking University People's Hospital&Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing,100044,China)
出处
《临床血液学杂志》
2023年第5期309-315,共7页
Journal of Clinical Hematology
基金
首都特色重点项目(No:Z221100007422008)
国家自然科学基金面上项目(No:82070185)。
关键词
微小残留病
急性髓细胞白血病
个体化治疗
minimal residual disease
acute myeloid leukemia
individual therapy
